Literature DB >> 12559680

Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.

Robert Palmer1, Robert Weiss, Randall M Zusman, Ann Haig, Susan Flavin, Brian MacDonald.   

Abstract

Nonsteroidal anti-inflammatory drugs interfere with certain antihypertensive therapies. In a double-blind study, 385 hypertensive patients stabilized on an angiotensin converting enzyme inhibitor were treated with nabumetone, celecoxib, ibuprofen, or placebo for 4 weeks. Ibuprofen caused significantly greater increases in systolic (P < .001) and diastolic (P < .01) blood pressures (BPs) compared to placebo, but not nabumetone or celecoxib. The proportion of patients with systolic BP increases of clinical concern at end point was significantly higher (P < .001) for the ibuprofen group (16.7%; 15 of 90), but not for the nabumetone group (5.5%; 5 of 91) or the celecoxib group (4.6%; 4 of 87) compared to the placebo group (1.1%; 1 of 91). Copyright 2003 American Journal of Hypertension, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559680     DOI: 10.1016/s0895-7061(02)03203-x

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

1.  Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France.

Authors:  Mai Duong; Francesco Salvo; Antoine Pariente; Abdelilah Abouelfath; Regis Lassalle; Cecile Droz; Patrick Blin; Nicholas Moore
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

2.  An overview of clinical pharmacology of Ibuprofen.

Authors:  Rabia Bushra; Nousheen Aslam
Journal:  Oman Med J       Date:  2010-07

Review 3.  Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

Authors:  Nicholas Moore
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

4.  A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.

Authors:  Kenji Ogata; Norito Takamura; Jin Tokunaga; Tetsuya Ikeda; Nao Setoguchi; Kazuhiro Tanda; Tetsuo Yamasaki; Toyotaka Nishio; Keiichi Kawai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-24       Impact factor: 2.441

Review 5.  Drug-Induced Hypertension: Focus on Mechanisms and Management.

Authors:  Alexandra R Lovell; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2017-05       Impact factor: 5.369

Review 6.  Celecoxib: a review of its use in the management of arthritis and acute pain.

Authors:  James E Frampton; Gillian M Keating
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 8.  Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.

Authors:  Thomas Hedner; Ola Samulesson; Peter Währborg; Hans Wadenvik; Kjell-Arne Ung; Anders Ekbom
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.

Authors:  Hisham Aljadhey; Wanzhu Tu; Richard A Hansen; Susan J Blalock; D Craig Brater; Michael D Murray
Journal:  BMC Cardiovasc Disord       Date:  2012-10-24       Impact factor: 2.298

Review 10.  Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2008       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.